English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background:  Whereas the cardiovascular safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors has been well reported, there is limited data from controlled clinical trials regarding the non-cardiovascular safety. This was the focus of our study.    Methods and Findings:  We systematically searched MEDLINE, EMBASE, and Cochrane Library (5 th  Sep 2018) for randomized controlled trials (RCTs) that reported safety data for SGLT2 inhibitors and placebo. Relative risks (RRs) and their 95% confidence intervals (CIs) were pooled using random-effects models. Seventy RCTs (83 studies enrolling 36,958 patients in 78 publications) were identified. SGLT2 inhibitors were associated with a lower risk of serious adverse events (RR 0.90, 95% CI 0.86 to 0.94,  P  < 0.001), death (RR 0.78, 95% CI 0.64 to 0.94,  P  < 0.05), gastroenteritis (RR 0.38, 95% CI 0.20 to 0.72,  P  < 0.05), arthralgia (RR 0.72, 95% CI 0.54 to 0.96,  P  < 0.05), hypertension (RR 0.61, 95% CI 0.50 to 0.75,  P  < 0.001), and edema/peripheral edema (RR 0.49, 95% CI 0.33 to 0.72,  P  < 0.001) compared to placebo. SGLT2 inhibitors were associated with higher risk of infections compared to placebo (RR 1.27, 95% CI 1.17 to 1.37,  P  < 0.001), especially for genital mycotic infection (GMI) (RR 3.71, 95% CI 3.19 to 4.32,  P  < 0.001). Other significant effects were observed for osmotic diuresis–related AEs (RR 2.73, 95% CI 2.20 to 3.40,  P  < 0.001), volume-related AEs (RR 1.26, 95% CI 1.08 to 1.46,  P  < 0.05), renal-related AEs (RR 1.36, 95% CI 1.02 to 1.80,  P  < 0.05), hypoglycemia (RR 1.18, 95% CI 1.10 to 1.26,  P  < 0.001), and increased blood ketone bodies (RR 2.00, 95% CI 1.01 to 3.97,  P  < 0.05). Subgroup and sensitivity analyses strengthened the robustness of primary results.    Conclusion:  Results from RCTs confirmed lower risk of death, serious adverse events, hypertension, and edema associated with type 2 diabetes mellitus (T2DM) patients treated with SGLT2 inhibitors when compared with placebo. The use of SGLT2 inhibitors were associated with higher risk of infection, osmotic diuresis, volume depletion effects, renal related AEs, and higher blood ketone bodies when compared with placebo.

frontiers in pharmacology

Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials